JavaScript is disabled. Please enable to continue!

Mobile search icon
Media Centre >> Press Releases 2014 >> 2014-11-12

Eurofins launches rapidust® - a patented on-site sampling and analysis system for mycotoxins in grains to offer grain industry broader risk protection within minutes

Sidebar Image

Eurofins Scientific (EUFI.PA), the global leader in food and feed testing, announces the launch of rapidust®, the first on-site test system for mycotoxins, including both representative sampling of grain lots and rapid analysis, to provide broader risk protection across the grain industry regarding mycotoxin contaminations.

Representative sampling is the key success factor for the correct assessment of a grain lot, as mycotoxins usually occur heterogeneously distributed throughout the lot. Reliable results at reasonable time effort are crucial to allow for fast and effective quality management in grain trading and processing. The rapidust®system entirely fulfills these requirements.

In contrast to conventional time- and labour-intensive grain sampling methods, the patented rapidust® procedure1 is based on dust sampling and analysis. Based on the proven fact that the contamination of the overall grain lot and its dust particles can be correlated, Eurofins now offers its customers unique certainty on the mycotoxin contamination of large grain lots within minutes. Representative dust samples can be easily taken with the mobile or fixed process integrated rapidust® sampling device, wherever grain is handled and transported - at the lorry, silo, ship or as an in-process control. Without any grinding the dust is directly extracted and analysed on-site by means of the rapidust® test kits. The results are immediately and reliably calculated for the entire grain lot by the rapidust® app. Thanks to an easily understandable traffic-light system, fast decisions on approval of grain lots and process control can be taken.

The rapidust® service is rounded off with customised system installation services, conventional on-site sampling services and the full access to the comprehensive portfolio of screening and confirmatory methods in the Eurofins laboratories under DIN EN ISO/IEC 17025:2005 accreditation.

With rapidust® Eurofins complements its comprehensive lab-based Risk-Orientated Mycotoxin and Biotoxin Testing2 package with an on-site product portfolio. Entering into the first test market Eurofins now offers customers full service for mycotoxin management along the grain value chain.

The Group's Competence Centre for Mycotoxin and Biotoxin Testing in Hamburg has been a pioneer in developing highly sensitive and innovative methods for trace amount detection of mycotoxins and biotoxins in food and feed for more than 20 years.

1 Eurofins rapidust® Mycotoxins Brochure: http://www.eurofins.de/media/10315289/rapidust_brochure_en.pdf

2 Eurofins Risk-orientated Mycotoxin and Biotoxin Testing : http://www.eurofins.de/media/7679837/mycotoxins_eng.pdf

 For more information, please contact:

Dr. Scarlett Biselli

Eurofins WEJ Contaminants GmbH    

Phone: +49 40 49 294 2002

Email: scarlettbiselli@eurofins.de

Eurofins Investor Relations

Phone: +32 2 766 1620

Email: ir@eurofins.com

Notes for the editor:

Eurofins - a global leader in bio-analysis

Eurofins Scientific is the world leader in food and pharmaceutical products testing. It is also number one in the world in the field of environmental laboratory services and one of the global market leaders in agroscience, genomics, discovery pharmacology and central laboratory services.

With 16,000 staff in more than 200 laboratories across 36 countries, Eurofins offers a portfolio of over 100,000 reliable analytical methods for evaluating the safety, identity, composition, authenticity, origin and purity of biological substances and products. The Group provides its customers with high-quality services, accurate results in time and expert advice by its highly qualified staff.

Eurofins is committed to pursuing its dynamic growth strategy by expanding both its technology portfolio and its geographic reach. Through R&D and acquisitions, the Group draws on the latest developments in the field of biotechnology and analytical chemistry to offer its clients unique analytical solutions and the most comprehensive range of testing methods.

As one of the most innovative and quality oriented international players in its industry, Eurofins is ideally positioned to support its clients' increasingly stringent quality and safety standards and the expanding demands of regulatory authorities around the world.

The shares of Eurofins Scientific are listed on the Euronext Paris Stock Exchange (ISIN FR0000038259, Reuters EUFI.PA, Bloomberg ERF FP).

Important disclaimer:

This press release contains forward-looking statements and estimates that involve risks and uncertainties. The forward-looking statements and estimates contained herein represent the judgement of Eurofins Scientific’ management as of the date of this release. These forward-looking statements are not guarantees for future performance, and the forward-looking events discussed in this release may not occur. Eurofins Scientific disclaims any intent or obligation to update any of these forward-looking statements and estimates. All statements and estimates are made based on the information available to the Company’s management as of the date of publication, but no guarantee can be made as to their validity.